Logo image of VNRX

VOLITIONRX LTD (VNRX) Stock Fundamental Analysis

NYSEARCA:VNRX - American Stock Exchange - US9286611077 - Common Stock

0.6081  -0.02 (-3.48%)

Fundamental Rating

2

Taking everything into account, VNRX scores 2 out of 10 in our fundamental rating. VNRX was compared to 191 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of VNRX have multiple concerns. VNRX is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VNRX has reported negative net income.
In the past year VNRX has reported a negative cash flow from operations.
VNRX had negative earnings in each of the past 5 years.
In the past 5 years VNRX always reported negative operating cash flow.
VNRX Yearly Net Income VS EBIT VS OCF VS FCFVNRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

VNRX has a worse Return On Assets (-248.10%) than 94.21% of its industry peers.
Industry RankSector Rank
ROA -248.1%
ROE N/A
ROIC N/A
ROA(3y)-129.77%
ROA(5y)-108.55%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VNRX Yearly ROA, ROE, ROICVNRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K -1K -2K

1.3 Margins

VNRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VNRX Yearly Profit, Operating, Gross MarginsVNRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50K -100K -150K -200K

More info and screens

0

2. Health

2.1 Basic Checks

VNRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
VNRX has more shares outstanding than it did 1 year ago.
VNRX has more shares outstanding than it did 5 years ago.
VNRX has a better debt/assets ratio than last year.
VNRX Yearly Shares OutstandingVNRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
VNRX Yearly Total Debt VS Total AssetsVNRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M

2.2 Solvency

VNRX has an Altman-Z score of -32.71. This is a bad value and indicates that VNRX is not financially healthy and even has some risk of bankruptcy.
VNRX's Altman-Z score of -32.71 is on the low side compared to the rest of the industry. VNRX is outperformed by 90.00% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -32.71
ROIC/WACCN/A
WACC8.76%
VNRX Yearly LT Debt VS Equity VS FCFVNRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M

2.3 Liquidity

VNRX has a Current Ratio of 0.24. This is a bad value and indicates that VNRX is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.24, VNRX is not doing good in the industry: 94.74% of the companies in the same industry are doing better.
VNRX has a Quick Ratio of 0.24. This is a bad value and indicates that VNRX is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.24, VNRX is not doing good in the industry: 94.21% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.24
Quick Ratio 0.24
VNRX Yearly Current Assets VS Current LiabilitesVNRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 32.08% over the past year.
VNRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 150.10%.
VNRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 326.41% yearly.
EPS 1Y (TTM)32.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
Revenue 1Y (TTM)150.1%
Revenue growth 3Y326.41%
Revenue growth 5YN/A
Sales Q2Q%187.22%

3.2 Future

Based on estimates for the next years, VNRX will show a very strong growth in Earnings Per Share. The EPS will grow by 46.12% on average per year.
VNRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 205.12% yearly.
EPS Next Y36.8%
EPS Next 2Y29.23%
EPS Next 3Y25.57%
EPS Next 5Y46.12%
Revenue Next Year52879.9%
Revenue Next 2Y227.94%
Revenue Next 3Y204.66%
Revenue Next 5Y205.12%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
VNRX Yearly Revenue VS EstimatesVNRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
VNRX Yearly EPS VS EstimatesVNRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 2 3 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VNRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VNRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VNRX Price Earnings VS Forward Price EarningsVNRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VNRX Per share dataVNRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3

4.3 Compensation for Growth

VNRX's earnings are expected to grow with 25.57% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.23%
EPS Next 3Y25.57%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VNRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VOLITIONRX LTD

NYSEARCA:VNRX (1/22/2025, 12:47:09 PM)

0.6081

-0.02 (-3.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)N/A N/A
Inst Owners8.87%
Inst Owner Change-0.05%
Ins Owners6.22%
Ins Owner Change29.17%
Market Cap56.35M
Analysts80
Price Target3.41 (460.76%)
Short Float %0.81%
Short Ratio1.77
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.16%
Min EPS beat(2)10.87%
Max EPS beat(2)17.44%
EPS beat(4)3
Avg EPS beat(4)11.06%
Min EPS beat(4)-1.1%
Max EPS beat(4)17.44%
EPS beat(8)6
Avg EPS beat(8)8.27%
EPS beat(12)7
Avg EPS beat(12)-69.64%
EPS beat(16)9
Avg EPS beat(16)-50.46%
Revenue beat(2)0
Avg Revenue beat(2)-37.67%
Min Revenue beat(2)-56.82%
Max Revenue beat(2)-18.52%
Revenue beat(4)0
Avg Revenue beat(4)-43.86%
Min Revenue beat(4)-56.82%
Max Revenue beat(4)-18.52%
Revenue beat(8)0
Avg Revenue beat(8)-47.33%
Revenue beat(12)0
Avg Revenue beat(12)-53.73%
Revenue beat(16)2
Avg Revenue beat(16)143.62%
PT rev (1m)-5.47%
PT rev (3m)1.98%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)8.41%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)25391.7%
Revenue NY rev (3m)25391.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 57.42
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.36
EYN/A
EPS(NY)-0.17
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS0.01
BVpS-0.24
TBVpS-0.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -248.1%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-129.77%
ROA(5y)-108.55%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 73.15%
Cap/Sales 83.87%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.24
Quick Ratio 0.24
Altman-Z -32.71
F-Score3
WACC8.76%
ROIC/WACCN/A
Cap/Depr(3y)121.05%
Cap/Depr(5y)141.52%
Cap/Sales(3y)574.67%
Cap/Sales(5y)4734.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
EPS Next Y36.8%
EPS Next 2Y29.23%
EPS Next 3Y25.57%
EPS Next 5Y46.12%
Revenue 1Y (TTM)150.1%
Revenue growth 3Y326.41%
Revenue growth 5YN/A
Sales Q2Q%187.22%
Revenue Next Year52879.9%
Revenue Next 2Y227.94%
Revenue Next 3Y204.66%
Revenue Next 5Y205.12%
EBIT growth 1Y5.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year6.71%
EBIT Next 3Y15.83%
EBIT Next 5YN/A
FCF growth 1Y-32.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-35.73%
OCF growth 3YN/A
OCF growth 5YN/A